Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
Ewa Fiorentino-Rozek, Head of Clinical Affairs at AliveDx, shared a post on LinkedIn:
“IVD of the Week: Blood Group Genotyping – Are We Ready for Routine Use?
Blood group genotyping has come a long way in recent years. It started as a specialized tool for identifying rare donors and solving complex antibody cases, but it’s increasingly being talked about as part of routine blood bank practice.
Compared to traditional serology, genotyping can:
– Detect blood group variants that serology can miss
– Improve matching for patients who receive frequent transfusions (like those with sickle cell disease or thalassemia
– Help manage rare donor inventories more effectively
Yet despite all this progress, many labs still rely mostly on serological methods. Making genotyping a routine part of blood banking isn’t simple. There are real hurdles:
– Cost – both for instruments and ongoing reagents
– Integration – adapting workflows and training staff
– Data interpretation – translating genotyping results into clear transfusion decisions
– Guidelines – not all regions have clear recommendations on when or how to implement routine genotyping
I’d love to hear from colleagues across labs, blood services, and industry:
– Is your center already using genotyping routinely, or only for special cases?
– What barriers are slowing down broader adoption where you work?
– Do you think genotyping will become standard practice in the next five years—or is that still further off?
Let’s share real-world experiences and thoughts on how to bridge the gap between promise and practice in blood group genotyping.
________
Hi, I’m Ewa, and I help In Vitro Diagnostics companies bring innovative products to market.
Follow me for insights on IVD regulations, performance evaluation, and industry trends.”
Stay updated with Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits